Bethanien hospital, Frankfurt Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial
2014
NCT02237261
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2014

Timeline

NOW
  • Now

Alternative names

Hematology/Oncology,Bethanien hospital, Im Pruefling 17-19, 60389 Frankfurt/M., Germany

Active Ingredients

Drugs in Phase 2 Trials (3)

bendamustine (treanda) (1 trial)

bortezomib (velcade) (1 trial)

prednisone (meticorten) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Multiple Myeloma (Phase 2)

Neoplasms, Plasma Cell (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 3